Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models
Sponsor: Fei Li
Summary
The objective of this study is to learn if bumetanide could alleviate the clinical symptoms in children with autism spectrum disorder (ASD), who has been predicted as high responders to bumetanide via a cytokine-based predictive model. The Eligible ASD participants identified as high responder to bumetanide will be randomly assigned to either the experimental group or the control group. Participants in the experimental group will receive bumetanide interventions, along with the behavioral interventions, for three months. Participants in the control group will only undergo behavioral interventions. The clinical symptoms and potential adverse effects will be closely monitored throughout the intervention period.
Official title: Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
3 Years - 6 Years
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2025-06-04
Completion Date
2026-05-30
Last Updated
2025-06-12
Healthy Volunteers
No
Conditions
Interventions
Bumetanide
Participants will receive bumetanide (0.5mg bid) for a period of three months.
Treatment as usual (TAU)
Participants will undergo treatment as usual, such as behavioral interventions
Locations (1)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China